对乙酰氨基酚过量的群体药代动力学分析:即释、缓释与改性释放剂型
该研究收集356名受试者、15个来源(含3项随机对照试验)的3033个对乙酰氨基酚血药浓度数据,建立线性二室群体药代动力学模型。结果显示三种剂型的吸收速率和生物利用度均随口服剂量增加而降低(p<0.00005),且降低程度为改性释放>缓释>即释。阿片类共摄入使暴露量(AUC)增至1.6倍。模拟100 g与10 g剂量显示,缓释剂型总体暴露低于等剂量即释剂的80%,改性释放剂型低于70%。作者认为延迟吸收可能干扰Rumack-Matthew列线图的使用,在治疗早期低估摄入严重程度。
要点
- 缓释和改性释放对乙酰氨基酚吸收更慢、Cmax更低、Tmax更晚,延迟吸收可能使Rumack-Matthew列线图在早期低估中毒严重程度(作者结论)。
- 模拟100 g与10 g剂量:缓释剂型总体暴露(AUC)低于等剂量即释剂的80%,改性释放剂型低于70%。
- 阿片类共摄入使对乙酰氨基酚暴露量(AUC)增至1.6倍(事后分析)。
- 三种剂型的吸收速率和生物利用度均随口服剂量增加而降低(p<0.00005),降低程度为改性释放>缓释>即释。
- 最终群体药代动力学模型为线性二室模型伴一阶(口服)吸收,基于356名受试者的3033个血药浓度数据。
适用人群与场景
- 对乙酰氨基酚过量或接受超治疗剂量(缓释或改性释放剂型)的受试者,数据来源于过量病例和随机对照试验。
红旗征与不能漏的情况
- 缓释和改性释放剂型的延迟吸收可能干扰Rumack-Matthew列线图的使用,在治疗早期低估摄入严重程度(作者结论)。
研究设计与关键结果
- 研究类型:群体药代动力学分析,数据来自15个来源(含3项随机对照试验),共356名受试者、3033个对乙酰氨基酚血药浓度。
- 3项随机对照试验共179名受试者接受即释剂型、122名接受缓释剂型、65名接受改性释放剂型。
- 最终群体药代动力学模型为线性二室模型伴一阶(口服)吸收。
- 协变量关系:三种剂型的对乙酰氨基酚吸收速率和生物利用度均随口服剂量增加而降低(p<0.00005),降低程度为改性释放>缓释>即释。
- 事后分析:阿片类共摄入使暴露量(AUC)增至1.6倍。
- 模拟100 g与10 g剂量:缓释剂型过量表现为吸收更慢、Cmax更低,总体暴露(AUC)低于等剂量即释剂的80%;改性释放剂型总体暴露低于等剂量即释剂的70%。
证据类型、等级与局限
- 证据类型:群体药代动力学建模与模拟研究(含3项随机对照试验数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,缓释和改性释放剂型的延迟吸收可能干扰Rumack-Matthew列线图的使用,在治疗早期低估摄入严重程度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The introduction of delayed release formulations of acetaminophen (APAP) has created concern about the role of formulation in overdose. We examined the APAP overdose pharmacokinetic (PK) profiles to assess the role of dose, coingestants and formulation: immediate release (IR), extended release (ER), and modified release (MR) on APAP pharmacokinetic measures.
METHODS: We collected by-subject APAP PK data: subject description, timed blood APAP concentrations, dose, and coingestants. We sought both overdose and randomized controlled trials (RCTs) for supratherapeutic doses involving ER or MR formulations. Data analysis and simulation used the non-linear mixed-effects modeling program NONMEM-version 7.4.
RESULTS: The final dataset comprised 3,033 [APAP] from 356 subjects and 15 sources including 3 RCTs (179 subjects receiving IR, 122 ER, 65 MR). The final population PK (PopPK) model was a linear 2-compartment model with first-order (oral) absorption. Covariate relationships included: APAP absorption rate and bioavailability decreased with increased oral dose (p < 0.00005) for all 3 formulations (MR > ER > IR). Post hoc analyses showed opioid coingestant increased exposure (area under the curve, AUC) by factor of 1.6. Simulations of 100 g vs 10 g doses for IR, ER and MR showed overdose of the ER formulation exhibits slower absorption and lower Cmax, overall exposure (AUC) is less than 80% of an equivalent dose of IR acetaminophen. The overall exposure for the MR formulation is less than 70% of an equivalent dose of IR.
CONCLUSIONS: Acetaminophen ER and MR formulations have slower absorption and decreased bioavailability leading to a lower Cmax and later Tmax than the IR formulation. These results have potential clinical implications because delayed absorption could confound use of the Rumack-Matthew nomogram by underestimating the severity of ingestion early in the course of treatment.
参考来源
- Spyker DA, Dart RC, Yip L, et al. Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations. Clin Toxicol (Phila). 2022. PMID: 36106921. doi:10.1080/15563650.2022.2114361
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。